Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- ErbB receptor / ligand network
- Ligand activated ERBB receptors (1)
- ERBB receptors and intracellular signaling
- Ligand activated ERBB receptors (2)
- Signaling from ErbB2 containing heterodimers
- ErbB2/ErbB4 heterodimers in embryonic growth
- Activated ErbB2/ErbB4 heterodimers in heart
- Ligand activated ERBB receptors (3)
- ErbB2/3 hetrodimers and downstream signaling
- ErbB2/ErbB3 heterodimers in embryonic growth
- Structural studies of ERBB receptors
- The extracellular region of ERBB receptors
- EGF binding induces a conformational change
- ErbB2 structure is similar to activated EGFR
- ERBB receptors and cancer - background
- ErbB2 detection in breast cancer
- ERBB receptors and cancer (1)
- ERBB receptors and cancer (2)
- ERBB targeted therapeutics in clinical use
- EGFR and human cancer
- EGFR and lung cancer
- Mutations in EGFR kinase domain
- EGFR and human cancer
- ErbB2 and human cancer
- Autocrine / paracrine ERBB activation
- Processing of EGF-related ligands
- Proteases and processing of pro-ligands
- ERBB targeted therapeutics in clinical use
- Structure of recombinant antibodies
- ERBB targeted therapeutics
- ERBB RTKs and intracellular signaling in cancer
- ErbB2 and Trastuzumab
- Targeting ErbB2 blockes tumor cell proliferation
- 4D5 blocks ErbB2 and Akt signaling
- 4D5 blocks cyclin E/Cdk2 kinase activity
- Targeting ErbB2 in cancer cells
- Mechanisms proposed for Trastuzumab
- ErbB2 and Trastuzumab
- Trastuzumab and rational drug development
- Trastuzumab efficacy
- ErbB2 and Trastuzumab
- Targeting ErbB2 blockes tumor cell proliferation
- ERB ligands overcome anti-proliferative activity
- Trastuzumab binds domain IV of ErbB2
- Conclusions and perspectives
Topics Covered
- ERBB receptor/ligand network
- Activation and intracellular signaling
- Developmental roles for ERBB2 containing heterodimers
- ERBB receptor structure
- Molecular alterations of ERBB receptors in cancer
- Targeting ERBB receptors in cancer
- In vivo and in vitro studies describing how ERBB receptor blockade impacts on cancer
- Resistance of cancer cells to ERBB inhibitors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hynes, N. (2007, October 1). The epidermal growth factor receptor family: roles in development and cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/MFMP8030.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Nancy Hynes has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
The epidermal growth factor receptor family: roles in development and cancer
A selection of talks on Biochemistry
Hide